Exp Clin Endocrinol Diabetes 2016; 124(10): 630-636
DOI: 10.1055/s-0042-109606
Article
© Georg Thieme Verlag KG Stuttgart · New York

Prevalence and Clinical Correlators of Undiagnosed Significant Depressive Symptoms Among Individuals with Type 2 Diabetes In A Mediterranean Population

J. Nicolau
1   Endocrinology and Nutrition Department, Hospital Son LLàtzer (Palma, Spain), University Institute of Health Sciences Research (IUNICS) and Health Research Institute of Palma (IdISPa)
,
R. Simó
2   Diabetes Research Unit, Endocrinology Division, Hospital Universitari Vall d’Hebron, Universistat Autònoma de Barcelona (Barcelona, Spain)
,
P. Sanchís
1   Endocrinology and Nutrition Department, Hospital Son LLàtzer (Palma, Spain), University Institute of Health Sciences Research (IUNICS) and Health Research Institute of Palma (IdISPa)
,
L. Ayala
1   Endocrinology and Nutrition Department, Hospital Son LLàtzer (Palma, Spain), University Institute of Health Sciences Research (IUNICS) and Health Research Institute of Palma (IdISPa)
,
R. Fortuny
3   Hormonal Laboratory Department, Hospital Son Llàtzer (Palma, Spain)
,
R. Rivera
1   Endocrinology and Nutrition Department, Hospital Son LLàtzer (Palma, Spain), University Institute of Health Sciences Research (IUNICS) and Health Research Institute of Palma (IdISPa)
,
L. Masmiquel
1   Endocrinology and Nutrition Department, Hospital Son LLàtzer (Palma, Spain), University Institute of Health Sciences Research (IUNICS) and Health Research Institute of Palma (IdISPa)
› Author Affiliations
Further Information

Publication History

received 03 April 2016
first decision 25 May 2016

accepted 01 June 2016

Publication Date:
20 July 2016 (online)

Abstract

Objective: To determine the frequency and clinical parameters, of clinically significant depressive symptoms among a type 2 diabetes (T2DM) sample from a Mediterranean area without an established diagnosis of depressive disorder (DD).

Methods: 320 subjects with T2DM were recruited randomly from Primary-Care settings and the Endocrine Department from a tertiary center in Mallorca (Spain). 91 healthy individuals matched by age, gender and BMI were used as controls. All participating patients graded by the presence of DD by using the “Beck Depression Inventory” (BDI), considering pathological a cut-off score equal or greater than 16.

Results: 27.2% T2DM subjects had significant symptoms of DD compared with 12.1% in the control group (p<0.01). BDI score was higher among T2DM when compared with controls (12±9.6 vs. 7.4±5, p<0.0001). The proportion of females (68% vs. 37%, p<0.0001), subjects without an active job (68% vs. 45%, p=0.01) and singles (38% vs. 18%, p=0.007) was greater among T2DM with a BDI≥16. Subjects with criteria for DD had a higher BMI (31.99±5.96 vs. 30.53±5.62, p=0.03). Fasting plasma glucose was higher among T2DM with a BDI≥16 (162±70 vs. 147±45 mg/dl, p=0.02) as well as HbA1c levels (7.9±1.8% vs. 7.4±1.4%, p=0.01), triglycerides (203±183 vs. 161±103 mg/dl; p=0.03) and LDL-cholesterol (112±31 vs. 104±35 mg/dl; p=0.03). Gender, marital status, BMI and triglycerides were independently related to the presence of DD after a logistic regression model.

Conclusions: Relevant depressive symptoms are more prevalent among Mediterranean T2DM subjects than in general population. Main clinical correlators of significant depressive symptoms are gender, marital status and BMI.

 
  • References

  • 1 Greden JF. Physical symptoms of depression: unmet needs. J Clin Psychiatry 2003; 64 (Suppl. 07) 5-11
  • 2 World Health Organization. Revised global burden of disease (GBD) 2002 estimates. 2005 Available from http://www.who.int/healthinfo/bodgbd2002revised/en/index.html
  • 3 Mezuk B, Eaton WW, Albrecht S et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31: 2383-2390
  • 4 Pouwer F, Geelhoed-Duijvestijn PH, Tack CJ et al. Prevalence of comorbid depression is high in out-patients with type 1 or type 2 diabetes mellitus. Results from three out-patient clinics in the Netherlands. Diabet Med 2010; 27: 217-224
  • 5 Li C, Ford ES, Strine TW et al. Prevalence of depression among US adults with diabetes: findings from the 2006 behavioural risk factor surveillance system. Diabetes Care 2008; 31: 105-107
  • 6 Lloyd CE, Roy T, Nouwen A et al. Epidemiology of depression in diabetes: International and cross-cultural issues. J Affect Disord 2012; 142 Suppl S22-S29
  • 7 Castro-Costa E, Dewey M, Stewart R et al. Prevalence of depressive symptoms and syndromes in later life in ten European countries: the SHARE study. Brit J Psychiatry 2007; 191: 393-401
  • 8 Copeland JR, Beekman AT, Braam AW et al. Depression among older people in Europe: The EURODEP studies. World Psychiatry 2004; 3: 45-49
  • 9 Prince MJ, Reischies F, Beekman AT et al. Development of the EURO-D scale- a European union initiative to compare symptoms of depression in 14 European centres. Brit J Psychiat 1999; 174: 330-338
  • 10 Zunzunegui MV, Minicuci N, Blumstein T et al. Gender differences in depressive symptoms among older adults: a cross-national comparison: The CLESA project. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 198-207
  • 11 Kok R, Avendano M, Bago d’Uva T et al. Can reporting heterogeneity explain differences in depressive symptoms across Europe?. Soc Indic Res 2012; 105: 191-210
  • 12 Rienks J, Dobson AJ, Mishra GD. Mediterranean dietary pattern and prevalence and incidence of depressive symptoms in mid-aged women; results from a large community-based prospective study. Eur J Clin Nutr 2013; 7: 5-82
  • 13 Sánchez-Villegas A, Delgado-Rodríguez M, Alonso A et al. Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/ University of Navarra follow-up (SUN) cohort. Arch Gen Psychiatry 2009; 66: 1090-1098
  • 14 Sánchez-Villegas A, Martínez-González MA, Estruch R et al. Mediterranean dietary pattern and depression: the PREDIMED randomized trial. BMC Medicine 2013; 1: 208-219
  • 15 Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23: 934-942
  • 16 Beck AT, Steer RA, Brown GA. Beck Depression Inventory-II (BDI-II). Manual. Oxford, England: Pearson; 1996
  • 17 Lustman PJ, Clouse RE, Griffith LS et al. Screening for depression in diabetes using the Beck Depression Inventory. Psychosom Med 1997; 59: 24-31
  • 18 Anderson RJ, Freedland KE, Clouse RE et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069-1078
  • 19 de Jonge P, Roy JF, Saz P et al. ZARADEMP investigators. Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia 2006; 49: 2627-2633
  • 20 Roy T, Lloyd CE. Epidemiology of depression and diabetes: A systematic review. J Affect Disord 2012; 142 (Suppl. 01) S8-S21
  • 21 Nouwen A, Winkley K, Twisk J et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010; 53: 2480-2486
  • 22 Leone T, Coast E, Narayanan S, de Graft Aikins A. Diabetes and depression comorbidity and socio-economic status in low and middle income countries (LMICs): a mapping of the evidence. Global Health 2012; 8: 39
  • 23 Renn BN, Feliciano L, Segal DL. The bidirectional relationship of depression and diabetes: A systematic review. Clin Psychol Rev 2011; 31: 1239-1246
  • 24 Finkelstein EA, Bray JW, Chen H et al. Prevalence and costs of major depression among elderly claimants with diabetes. Diabetes Care 2003; 26: 415-420
  • 25 Nichols L, Barton PL, Glazner J et al. Diabetes, minor depression and health care utilization and expenditures: a retrospective database study. Cost Eff Resour Alloc 2007; 5: 4
  • 26 Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002; 25: 464-470
  • 27 Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment and pathophysiology. Neuropsychopharmacology 2011; 36: 2375-2394
  • 28 Richardson LK, Egede LE, Mueller M et al. Longitudinal effects of depression on glycemic control in veterans with type 2 diabetes. Gen Hosp Psychiatry 2008; 30: 509-514
  • 29 Aikens JE, Perkins DW, Lipton B et al. Longitudinal analysis of depressive symptoms and glycemic control in type 2 diabetes. Diabetes Care 2009; 32: 1177-1181
  • 30 de Groot M, Jacobson AM, Samson JA et al. Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus. J Psychosomatic Res 1999; 46: 425-435
  • 31 de Groot M, Anderson R, Freedland KE et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001; 63: 619-630
  • 32 Katon WJ, Young BA, Russo J et al. Association of depression with increased risk of severe hypoglycaemic episodes in patients with diabetes. Ann Fam Med 2013; 11: 245-250
  • 33 Surwit RS, van Tilburg MA, Parekh PI et al. Treatment regimen determines the relationship between depression and glycemic control. Diabetes Res Clin Pract 2005; 69: 78-80
  • 34 Duru NS, Civilibal M, Elevli M. Quality of life and psychological screening in children with type 1 diabetes and their mothers. Exp Clin Endocrinol Diabetes 2016; 124: 105-10
  • 35 Kloos C, Müller N, Hartmann P et al. High quality of diabetes care based upon individualised treatment goals – a cross sectional study in 4784 patients in Germany. Exp Clin Endocrinol Diabetes 2016; 124: 294-299
  • 36 Lustman PJ, Clouse RE, Nix BD et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, doubleblind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 521-529
  • 37 Lustman PJ, Freedland KE, Griffith LS et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diab Care 2000; 23: 618-623
  • 38 Amsterdam JD, Shults J, Rutherford N et al. Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus. Neuropsychobiology 2006; 54: 208-214
  • 39 Paile-Hyvaärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC. Fam Pract 2007; 8: 34-37
  • 40 Ghaeli P, Shahsavand E, Mesbahi M et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. Clin Psychopharmacol 2004; 24: 386-388
  • 41 Nicolau J, Rivera R, Francés C et al. Treatment of depression in type 2 diabetic patients: Effects on depressive symptoms, quality of life and metabolic control. Diabetes Res Clin Pract. 2013; 101: 148-152
  • 42 American Diabetes Association. Standards of medical care 2015. Diabetes Care 2015; 38 (Suppl. 01) S1-S93